User: TahirAmin Topic: IP
Category: drugs :: india
Last updated: Nov 14 2017 16:45 IST RSS 2.0
 
1 to 20 of 6,088    
After 15 years, Ranjit Shahani steps down as Novartis MD 14.11.2017 Rediff: Business
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
Also found in: [+]
Ranjit Shahani steps down at Novartis after two decades 13.11.2017 All Companies Stories
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
Also found in: [+]
Laurus Labs Records Healthy Performance, PAT Grows at 19pc in H1 FY18 13.11.2017 New Kerala: Business India
Laurus Labs Records Healthy Performance, PAT Grows at 19pc in H1 FY18
Also found in: [+]
Drug firm Pfizer Q2 net dips 12% to Rs 111 cr 10.11.2017 Latest News
Standalone revenue from operations rose to Rs 571.11 crore as against Rs 557.66 crore for same period year ago
Also found in: [+]
No dearth of suitors for consumer health business, says Pfizer 1.11.2017 Business Standard: Companies & Industry
Pfizer said the supply challenges would have a negative impact of "several hundred million dollars" this year, moderating in 2018
Also found in: [+]
Pfizer to start auction process for its consumer healthcare unit in Nov 26.10.2017 All Companies Stories
The prospective sale was first mooted on Oct 10, when Pfizer said it was considering strategic options for the unit
Also found in: [+]
How UCLA is fighting proxy patent battle for expensive cancer drug in India 18.10.2017 Business Standard: Today
UCLA appears to be representing the pharma firms Pfizer, Medivation and Astellas in its battle. They aren't telling the Delhi high court about this
Also found in: [+]
Base Erosion and Profit Shifting guidelines stump MNCs 14.10.2017 ET: Pharma
Under BEPS, multinationals will be required to declare details of revenues earned, taxes paid, employees hired, supply chain management in every country they operate in.
Also found in: [+]
Activists challenge Pneumonia vaccine patent in Delhi High Court 14.10.2017 DNA: Mumbai
Activists have challenged the patent claims of pharma giant Pfizer on a vaccine for pneumonia in the Delhi High Court. Médecins Sans Frontières or Doctors Without Borders (India) has filed a petition to overturn the patent granted earlier this year, on August 13 by the Indian Patent Office to Pfizer. “India has dashed hopes for improved access to an affordable PCV13 when it granted a patent to Pfizer for its PCV 13 product, marketed as Prevnar13, which will expire only in 2026,” a statement issued by MSF said. In the petition, MSF argues that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious. MSF argued that the mere addition of serotypes to the already established 7-valent vaccine did not involve a technical advancement – it was merely a tactic to preserve Pfizer’s monopoly for many more years. The decision also has broader implications, as it indicates a ...
Also found in: [+]
MSF drags govt to Delhi HC over Pfizer's pneumonia vaccine patent 14.10.2017 ET: Pharma
The Indian patent office granted Pfizer a patent for its vaccine PCV13 (13-valent pneumococcal conjugate vaccine), sold here under the brand ‘Prevenar13’ for over 10 years.
Also found in: [+]
Pfizer may sell or spin off its $15-billion consumer healthcare business 10.10.2017 Business Standard: Front Page Headlines
Germany's Merck KGaA is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion
Also found in: [+]
Malaysia issues compulsory license to Hepatitis C drug 9.10.2017 HBL: Home
This reignites discussion on compulsory license in India
Also found in: [+]
Pesticide producers have offered to voluntarily reduce prices: Rajju Shroff, UPL 29.9.2017 ET: Opinion
MRP could be reduced by 5% and pesticides makers have asked for two to three months to implement this.
Also found in: [+]
Built on bias 26.9.2017 FrontLine: Home
The draft pharmaceutical policy, in its present form, is aimed at securing the interests of the industry rather than making affordable healthcare a reality. By T.K. RAJALAKSHMI
Also found in: [+]
India needs to push for a new deal 19.9.2017 Hindu: Lead
It must reopen the discussion on balancing the global intellectual property system with development
Also found in: [+]
U.S. STOCKS ON THE MOVE-Oracle, Genworth, Airlines, Carnival Corp, Mirati Therapeutics 15.9.2017 TOI: Intl Business
MARKETS-USA-STOCKS/PULSE:BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Genworth, Airlines, Carnival Corp, Mirati Therapeutics
Also found in: [+]
Challenge of Allergan tribal patent deal in uncharted legal territory 15.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/ (CORRECTED):REFILE-Challenge of Allergan tribal patent deal in uncharted legal territory
Also found in: [+]
Pharma companies inflating R&D costs? 14.9.2017 TOI: India
Also found in: [+]
Mylan says Allergan misusing tribal sovereignty in patent dispute 13.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/MYLAN:Mylan says Allergan misusing tribal sovereignty in patent dispute
Also found in: [+]
U.S. tribal patent deal could have big impact on generic drug market 12.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/MOHAWK:U.S. tribal patent deal could have big impact on generic drug market
Also found in: [+]
1 to 20 of 6,088